Table 1 Patients, disease, and transplant characteristics
Variables | ||
|---|---|---|
Follow-up (months) | Median (range) | 31 (2–79) |
Patient age (years) | Median (range) | 32 (18–76) |
Year of Tx | Median (range) | 2012 (2007–2014) |
Patient sex | Female | 80 (39%) |
Male | 127 (61%) | |
Karnofsky at Tx | ≥90% | 128 (69%) |
Previous autologous Tx | Yes | 14 (7%) |
Disease status at Tx | CR1 | 91 (44%) |
CR2+ | 58 (28%) | |
Advanced disease | 59 (28%) | |
Immunophenotype | B ALL | 100 (66%) |
T ALL | 51 (34%) | |
CNS involvement | Yes | 10 (10%) |
Status of MRD at Tx | Positive | 45 (49%) |
Negative | 46 (51%) | |
Cytogenetics | Ph-positive | 46 (32%) |
Ph-negative | 96 (68%) | |
Normal karyotype | 37 | |
Abnormal karyotype | 32 | |
t(4;11) | 4 | |
t(1;19) | 5 | |
t(12;21) | 2 | |
Donor age | Median (range) | 39 (12–74) |
F donor/M recipient | Yes | 63 (30%) |
Stem cell source | BM | 89 (43%) |
PB | 119 (57%) | |
CMV D/R | Neg to neg | 24 (12%) |
Pos to neg | 20 (10%) | |
Neg to pos | 30 (15%) | |
Pos to pos | 127 (63%) | |
Donor kinship | Parents | 49 (37%) |
Sibling | 51 (38%) | |
Child | 25 (19%) | |
Others relatives | 8 (6%) | |
Conditioning regimen | MAC | 137 (66%) |
TBI-based (8–12 Gy) | 63 | |
Cy TBI | 29 | |
Flu TBI | 31 | |
Other TBI | 3 | |
Chemo-based | 74 | |
TBF | 38 | |
Bu Cy | 1 | |
Bu Flu | 3 | |
Flu Mel | 2 | |
Treo-based | 5 | |
Cy Flu | 5 | |
Cy AraC Bu | 19 | |
Cy Ida | 1 | |
RIC | 71 (34%) | |
TBI based (<6 Gy) | 26 | |
Cy TBI | 15 | |
Flu TBI | 11 | |
Chemo-based | 45 | |
TBF | 8 | |
Bu Flu | 4 | |
Bu ± others | 1 | |
Flu Mel | 6 | |
Bu Mel | 1 | |
Treo-based | 11 | |
Cy Flu | 11 | |
Cy thiotepa Bu | 1 | |
Cy AraC Bu | 1 | |
GVHD prophylaxis | PT-Cy | 118 (57%) |
ATG-based | 90 (43%) | |